MCID: THY102
MIFTS: 57

Thyroid Cancer, Nonmedullary, 2

Categories: Genetic diseases, Rare diseases, Cancer diseases, Endocrine diseases

Aliases & Classifications for Thyroid Cancer, Nonmedullary, 2

MalaCards integrated aliases for Thyroid Cancer, Nonmedullary, 2:

Name: Thyroid Cancer, Nonmedullary, 2 53
Follicular Thyroid Carcinoma 12 49 28 14 69
Thyroid Carcinoma, Follicular 53 72 49 13
Thyroid Cancer, Follicular 49 28 69
Nmtc2 53 71
Follicular Adenocarcinoma, Well Differentiated 12
Follicular Carcinoma of the Thyroid Gland 12
Thyroid Carcinoma, Follicular, Somatic 53
Thyroid Cancer, Non-Medullary, 2 71
Thyroid Follicular Carcinoma 51
Thyroid Gland Adenocarcinoma 69
Adenocarcinoma, Follicular 41
Follicular Adenocarcinoma 12
Follicular Thyroid Cancer 51
Thyroid Adenocarcinoma 12
Follicular Carcinoma 12
Ftc 49

Characteristics:

OMIM:

53
Inheritance:
autosomal dominant


HPO:

31
thyroid cancer, nonmedullary, 2:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 53 188470
Disease Ontology 12 DOID:3962
NCIt 46 C8054
SNOMED-CT via HPO 65 263681008

Summaries for Thyroid Cancer, Nonmedullary, 2

OMIM : 53 Nonmedullary thyroid cancer (NMTC) comprises thyroid cancers of follicular cell origin and accounts for more than 95% of all thyroid cancer cases. The remaining cancers originate from parafollicular cells (medullary thyroid cancer, MTC; 155240). NMTC is classified into 4 groups: papillary, follicular, Hurthle cell (607464), and anaplastic. Approximately 5% of NMTC is hereditary, occurring as a minor component of a familial cancer syndrome (e.g., familial adenomatous polyposis, 175100, Carney complex, 160980) or as a primary feature (familial NMTC or FNMTC). Papillary thyroid cancer (PTC) is the most common histologic subtype of FNMTC, accounting for approximately 85% of cases (summary by Vriens et al., 2009). Follicular thyroid cancer (FTC) accounts for approximately 15% of NMTC and is defined by invasive features that result in infiltration of blood vessels and/or full penetration of the tumor capsule, in the absence of the nuclear alterations that characterize papillary carcinoma. FTC is rarely multifocal and usually does not metastasize to the regional lymph nodes but tends to spread via the bloodstream to the lung and bones. An important histologic variant of FTC is the oncocytic (Hurthle cell, oxyphilic) follicular carcinoma composed of eosinophilic cells replete with mitochondria (summary by Bonora et al., 2010). For a general phenotypic description and a discussion of genetic heterogeneity of NMTC, see NMTC1 (188550). (188470)

MalaCards based summary : Thyroid Cancer, Nonmedullary, 2, also known as follicular thyroid carcinoma, is related to thyroid carcinoma, familial medullary and differentiated thyroid carcinoma, and has symptoms including abnormality of metabolism/homeostasis, follicular thyroid carcinoma and non-medullary thyroid carcinoma. An important gene associated with Thyroid Cancer, Nonmedullary, 2 is SRGAP1 (SLIT-ROBO Rho GTPase Activating Protein 1), and among its related pathways/superpathways are Ras signaling pathway and mTOR signaling pathway (KEGG). The drugs Salmon Calcitonin and Iodine have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lung and bone, and related phenotypes are Decreased viability and Decreased viability

UniProtKB/Swiss-Prot : 71 Thyroid cancer, non-medullary, 2: A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.

Disease Ontology : 12 A thyroid carcinoma that has material basis in follicular cells.

Wikipedia : 72 Follicular thyroid cancer or follicular thyroid carcinoma accounts for 15% of thyroid cancer and occurs... more...

Related Diseases for Thyroid Cancer, Nonmedullary, 2

Diseases in the Thyroid Cancer, Nonmedullary, 1 family:

Thyroid Cancer, Nonmedullary, 2 Thyroid Cancer, Nonmedullary, 3
Thyroid Cancer, Nonmedullary, 4 Thyroid Cancer, Nonmedullary, 5

Diseases related to Thyroid Cancer, Nonmedullary, 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Related Disease Score Top Affiliating Genes
1 thyroid carcinoma, familial medullary 32.3 CALCA NKX2-1 RET TG
2 differentiated thyroid carcinoma 31.9 BRAF HRAS NKX2-1 NRAS PAX8 PPARG
3 thyroiditis 30.7 CALCA RET TG THRB TPO TSHR
4 goiter 29.8 CALCA NKX2-1 PAX8 TG THRB TPO
5 follicular adenoma 29.3 CALCA LGALS3 MINPP1 NKX2-1 PAX8 PTEN
6 thyroid cancer, nonmedullary, 1 29.3 BRAF CALCA HRAS LGALS3 NKX2-1 PAX8
7 familial papillary or follicular thyroid carcinoma 12.1
8 trabecular follicular adenocarcinoma 12.1
9 papillary follicular thyroid adenocarcinoma 11.9
10 tumoral calcinosis, hyperphosphatemic, familial 11.5
11 thyroid carcinoma, hurthle cell 11.1
12 mucoepidermoid thyroid carcinoma 10.7 CALCA TG
13 ovarian melanoma 10.6 HRAS NRAS PTEN
14 schimmelpenning-feuerstein-mims syndrome 10.6 HRAS NRAS
15 chromosome 14q11-q22 deletion syndrome 10.6 HRAS NKX2-1
16 suppurative thyroiditis 10.6 CALCA TG
17 familial thyroid dyshormonogenesis 10.6 TG TPO
18 acral lentiginous melanoma 10.6 BRAF NRAS PTEN
19 subacute lymphocytic thyroiditis 10.6 TG TPO
20 ovarian germ cell cancer 10.6 NKX2-1 RET TG
21 thyroid sarcoma 10.6 CALCA TG
22 suppression of tumorigenicity 12 10.6 BRAF HRAS PTEN
23 plummer's disease 10.6 TG THRB TPO
24 ovarian cystic teratoma 10.6 CALCA NKX2-1 TG
25 myxedema 10.5 TG TPO TSHR
26 subacute thyroiditis 10.5 TG TPO TSHR
27 spitz nevus 10.5 BRAF HRAS
28 clivus chordoma 10.5 HRAS PTEN
29 histiocytic sarcoma 10.5 BRAF LGALS3 PTEN
30 giant cell glioblastoma 10.5 BRAF PPARG PTEN
31 autoimmune disease of endocrine system 10.5 TG TPO TSHR
32 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.5 TG TPO TSHR
33 small cell carcinoma 10.5 CALCA NKX2-1 PTEN
34 water-clear cell adenoma 10.5 PAX8 TG
35 malignant ovarian surface epithelial-stromal neoplasm 10.5 HRAS NME1 PAX8
36 cell type cancer 10.5 HRAS NKX2-1 NRAS PTEN
37 ovary epithelial cancer 10.5 HRAS NME1 PAX8
38 melanoma, cutaneous malignant 1 10.5 BRAF HRAS NRAS PTEN
39 ovarian germ cell teratoma 10.5 NKX2-1 NRAS RET TG
40 cowden disease 10.5 CALCA PTEN RET TG
41 goiter, multinodular 1, with or without sertoli-leydig cell tumors 10.5 TG TPO
42 colonic benign neoplasm 10.5 BRAF HRAS PPARG
43 athyreosis 10.5 NKX2-1 PAX8 TG TSHR
44 pendred syndrome 10.5 PAX8 TG TPO
45 hypersensitivity reaction disease 10.5 TG TPO TSHR
46 tumor suppressor gene on chromosome 11 10.5 BRAF PTEN
47 endemic goiter 10.5 CALCA TG TPO TSHR
48 nontoxic goiter 10.5 CALCA TG TPO TSHR
49 neonatal hypothyroidism 10.5 PAX8 TG TPO TSHR
50 mixed type thymoma 10.5 PAX8 PTEN

Graphical network of the top 20 diseases related to Thyroid Cancer, Nonmedullary, 2:



Diseases related to Thyroid Cancer, Nonmedullary, 2

Symptoms & Phenotypes for Thyroid Cancer, Nonmedullary, 2

Symptoms via clinical synopsis from OMIM:

53
Neoplasia:
nonmedullary thyroid carcinoma (papillary and follicular)


Clinical features from OMIM:

188470

Human phenotypes related to Thyroid Cancer, Nonmedullary, 2:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis 31 HP:0001939
2 follicular thyroid carcinoma 31 HP:0006731
3 non-medullary thyroid carcinoma 31 HP:0040198

GenomeRNAi Phenotypes related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.6 HRAS
2 Decreased viability GR00221-A-1 9.6 KDR NRAS PPARG RET HRAS
3 Decreased viability GR00221-A-2 9.6 KDR PPARG RET HRAS
4 Decreased viability GR00221-A-3 9.6 HRAS KDR NRAS PPARG
5 Decreased viability GR00221-A-4 9.6 KDR PPARG RET
6 Decreased viability GR00231-A 9.6 RET
7 Decreased viability GR00301-A 9.6 RET

MGI Mouse Phenotypes related to Thyroid Cancer, Nonmedullary, 2:

43 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.46 BRAF DIO2 HRAS NKX2-1 NME1 NRAS
2 growth/size/body region MP:0005378 10.45 DIO2 HRAS KDR NKX2-1 NME1 NRAS
3 homeostasis/metabolism MP:0005376 10.45 BRAF DIO2 HRAS KDR LGALS3 NKX2-1
4 behavior/neurological MP:0005386 10.4 THRB TSHR BRAF HRAS KDR LGALS3
5 cardiovascular system MP:0005385 10.39 BRAF HRAS KDR LGALS3 NKX2-1 NRAS
6 cellular MP:0005384 10.38 BRAF KDR LGALS3 NKX2-1 NRAS PAX8
7 mortality/aging MP:0010768 10.35 BRAF HRAS KDR LGALS3 NKX2-1 NME1
8 hematopoietic system MP:0005397 10.3 BRAF KDR LGALS3 NRAS PPARG PTEN
9 digestive/alimentary MP:0005381 10.29 BRAF DIO2 HRAS LGALS3 NKX2-1 NRAS
10 immune system MP:0005387 10.28 BRAF KDR LGALS3 NRAS PPARG PTEN
11 nervous system MP:0003631 10.25 BRAF HRAS KDR LGALS3 NKX2-1 NME1
12 neoplasm MP:0002006 10.23 BRAF HRAS LGALS3 NKX2-1 NME1 NRAS
13 craniofacial MP:0005382 10.14 BRAF HRAS KDR NRAS PAX8 THRB
14 integument MP:0010771 10.13 PTEN BRAF HRAS KDR LGALS3 NME1
15 normal MP:0002873 10.11 NKX2-1 NRAS PAX8 PPARG PTEN RASSF1
16 liver/biliary system MP:0005370 10.1 PPARG PTEN RASSF1 NME1 NRAS BRAF
17 limbs/digits/tail MP:0005371 10.05 PTEN RET THRB TPO TSHR NRAS
18 hearing/vestibular/ear MP:0005377 10.04 BRAF PAX8 PPARG THRB TPO TSHR
19 no phenotypic analysis MP:0003012 10.01 HRAS KDR NKX2-1 NRAS PAX8 PPARG
20 renal/urinary system MP:0005367 9.92 BRAF DIO2 HRAS LGALS3 PAX8 PPARG
21 reproductive system MP:0005389 9.91 LGALS3 NKX2-1 PAX8 PPARG PTEN RET
22 skeleton MP:0005390 9.77 HRAS KDR LGALS3 NKX2-1 NRAS PAX8
23 respiratory system MP:0005388 9.76 BRAF HRAS KDR LGALS3 NKX2-1 PTEN
24 vision/eye MP:0005391 9.28 BRAF KDR NRAS PAX8 PPARG PTEN

Drugs & Therapeutics for Thyroid Cancer, Nonmedullary, 2

Drugs for Thyroid Cancer, Nonmedullary, 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Salmon Calcitonin Approved, Investigational Phase 3,Phase 2 47931-85-1 16129616
2
Iodine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 7553-56-2 807
3 Anti-Infective Agents Phase 2, Phase 3,Phase 1,Not Applicable
4 Bone Density Conservation Agents Phase 3,Phase 2
5 calcitonin Phase 3,Phase 2
6 Calcitonin Gene-Related Peptide Phase 3,Phase 2
7 Hormones Phase 3,Phase 2,Phase 1
8 Anti-Infective Agents, Local Phase 2, Phase 3,Phase 1,Not Applicable
9 cadexomer iodine Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
10 Micronutrients Phase 2, Phase 3,Phase 1,Not Applicable
11 Trace Elements Phase 2, Phase 3,Phase 1,Not Applicable
12 Hormone Antagonists Phase 3,Phase 2
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
14
Rosiglitazone Approved, Investigational Phase 2,Phase 1 122320-73-4 77999
15
Everolimus Approved Phase 2 159351-69-6 6442177
16
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
17
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
18
Indinavir Approved Phase 2 150378-17-9 5362440
19
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
20
Azacitidine Approved, Investigational Phase 2,Phase 1 320-67-2 9444
21
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
22
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
23
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
24
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
25
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
26
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
27
Gefitinib Approved, Investigational Phase 2,Not Applicable 184475-35-2 123631
28
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
29
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
30
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
31
Tamoxifen Approved Phase 2 10540-29-1 2733526
32
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
33
Trametinib Approved Phase 2 871700-17-3 11707110
34
Lenalidomide Approved Phase 2,Phase 1 191732-72-6 216326
35
Dabrafenib Approved, Investigational Phase 2 44462760 44516822
36
Lenvatinib Approved, Investigational Phase 2 417716-92-8
37
Pembrolizumab Approved Phase 2 1374853-91-4
38
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
39
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
41
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
42
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
43
Maleic acid Experimental Phase 2,Phase 1 110-16-7 444266
44
Doxil Approved June 1999 Phase 2 31703
45
Camptothecin Experimental Phase 1, Phase 2 7689-03-4
46
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
47 Hypoglycemic Agents Phase 2,Phase 1
48 Anti-Bacterial Agents Phase 2,Phase 1
49 Antibiotics, Antitubercular Phase 2
50 Antifungal Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 54)

# Name Status NCT ID Phase Drugs
1 A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
2 IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
3 Iodine I 131 With or Without Thyroid-Stimulating Hormone in Treating Patients Who Have Undergone Surgery for Thyroid Cancer Active, not recruiting NCT00415233 Phase 3
4 Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer Unknown status NCT00098852 Phase 2 rosiglitazone maleate
5 Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer Unknown status NCT01118065 Phase 2 everolimus
6 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
7 Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 Completed NCT00085293 Phase 2 Decitabine
8 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00104871 Phase 2 Bortezomib
9 Thalidomide in Treating Patients With Thyroid Cancer Completed NCT00026533 Phase 2 thalidomide
10 Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer Completed NCT00251316 Phase 2 Lithium Carbonate;Placebo
11 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
12 Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine Completed NCT00098813 Phase 2 romidepsin
13 Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer Completed NCT00118248 Phase 2 tanespimycin
14 Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00729157 Phase 2
15 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer Completed NCT00519896 Phase 2 sunitinib malate
16 Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer Completed NCT00134043 Phase 2 vorinostat
17 Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer Completed NCT00061906 Phase 2 celecoxib
18 Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy Completed NCT00095836 Phase 2 Gefitinib
19 Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer Completed NCT01164176 Phase 2 everolimus
20 A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer Completed NCT00121628 Phase 2 AMG 706
21 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
22 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
23 Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers Recruiting NCT01631552 Phase 1, Phase 2 IMMU-132
24 Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02393690 Phase 2 Selumetinib
25 Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02152995 Phase 2 Trametinib
26 REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas Active, not recruiting NCT00287287 Phase 2 Lenalidomide
27 Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer Active, not recruiting NCT00537095 Phase 2 Vandetanib
28 Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Active, not recruiting NCT01723202 Phase 2 dabrafenib;trametinib
29 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Active, not recruiting NCT01811212 Phase 2 Cabozantinib S-malate
30 Sunitinib in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery Active, not recruiting NCT00381641 Phase 2 Sunitinib Malate
31 Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer Active, not recruiting NCT01208051 Phase 1, Phase 2 Cediranib Maleate;Lenalidomide
32 Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery Not yet recruiting NCT02973997 Phase 2 Lenvatinib
33 Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer Terminated NCT00095693 Phase 2 sorafenib tosylate
34 A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors Completed NCT01100619 Phase 1 rosiglitazone;XL184
35 Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer Completed NCT00004062 Phase 1 azacitidine;liothyronine sodium
36 Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery Completed NCT01413113 Phase 1 pazopanib hydrochloride
37 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
38 Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases Completed NCT00062348 Phase 1 boronophenylalanine-fructose complex;sodium borocaptate
39 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
40 NGR-TNF in Treating Patients With Advanced Solid Tumors Completed NCT00098943 Phase 1
41 SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib
42 Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer Active, not recruiting NCT00470496 Phase 1 HPPH;photodynamic therapy
43 S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Withdrawn NCT00937417 Phase 1 docetaxel;vandetanib
44 Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study Completed NCT01927887 Not Applicable Ferumoxytol
45 Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm Completed NCT01433809 Not Applicable
46 Testicular Function After Iodine 131 Therapy in Papillary Carcinoma Patients Completed NCT01150318 Not Applicable Administration of 131 iodine
47 Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment Completed NCT01441154
48 Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer Completed NCT00068497 Not Applicable gefitinib
49 Iodine I 131 in Treating Patients With Thyroid Cancer Completed NCT00416949 Not Applicable
50 Diagnostic and Prognostic Significance of Computerized Cytologic Morphometry of the Thyroid Neoplasm Recruiting NCT03105648

Search NIH Clinical Center for Thyroid Cancer, Nonmedullary, 2

Cochrane evidence based reviews: adenocarcinoma, follicular

Genetic Tests for Thyroid Cancer, Nonmedullary, 2

Genetic tests related to Thyroid Cancer, Nonmedullary, 2:

# Genetic test Affiliating Genes
1 Thyroid Cancer, Follicular 28 HRAS MINPP1 NRAS PTEN SRGAP1
2 Follicular Thyroid Carcinoma 28

Anatomical Context for Thyroid Cancer, Nonmedullary, 2

MalaCards organs/tissues related to Thyroid Cancer, Nonmedullary, 2:

38
Thyroid, Lung, Bone, Lymph Node

Publications for Thyroid Cancer, Nonmedullary, 2

Articles related to Thyroid Cancer, Nonmedullary, 2:

(show top 50) (show all 355)
# Title Authors Year
1
A six-gene panel to label follicular adenoma, low- and high-risk follicular thyroid carcinoma. ( 29298844 )
2018
2
A case of metastatic follicular thyroid carcinoma complicated with Graves' disease after total thyroidectomy. ( 28883260 )
2017
3
Follicular thyroid carcinoma but not adenoma recruits tumor-associated macrophages by releasing CCL15. ( 26875556 )
2016
4
ST6GalNAcII mediates tumor invasion through PI3K/Akt/NF-I_B signaling pathway in follicular thyroid carcinoma. ( 26820593 )
2016
5
Follicular thyroid carcinoma in a male adolescent with Williams-Beuren syndrome. ( 27116698 )
2016
6
miR-4299 mediates the invasive properties and tumorigenicity of human follicular thyroid carcinoma by targeting ST6GALNAC4. ( 26715099 )
2016
7
The Diagnostic Usefulness of HMGA2, Survivin, CEACAM6, and SFN/14-3-3 I' in Follicular Thyroid Carcinoma. ( 25812733 )
2015
8
Follicular thyroid carcinoma with skull metastases. ( 25797278 )
2015
9
Low frequency of PAX8-PPARI^ rearrangement in follicular thyroid carcinomas in Japanese patients. ( 25708358 )
2015
10
Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report. ( 25886034 )
2015
11
Missed Initial Diagnosis of Malignant Struma Ovarii Containing Follicular Thyroid Carcinoma: Metastatic Pulmonary Recurrence 17 yr After Ovariectomy. ( 26262453 )
2015
12
Role of GPER1, EGFR and CXCR1 in differentiating between malignant follicular thyroid carcinoma and benign follicular thyroid adenoma. ( 26617848 )
2015
13
Metastatic follicular thyroid carcinoma masquerading as olfactory neuroblastoma: with skull-base, cranium, paranasal sinus, lung, and diffuse bone metastases. ( 25569410 )
2015
14
Difference between papillary and follicular thyroid carcinoma outcomes: an experience from Egyptian institution. ( 25859412 )
2015
15
Follicular thyroid carcinoma in patient followed for Graves' disease. An exceptional eventuality. ( 27126433 )
2015
16
The impact of CLAUDIN-1 on follicular thyroid carcinoma aggressiveness. ( 26219679 )
2015
17
Clinical significance of integrin I^6 as a tumor recurrence factor in follicular thyroid carcinoma. ( 24844802 )
2014
18
Follicular thyroid carcinoma characterized by abundant stromal components with chondroid and osseous metaplasia in a dog. ( 24805905 )
2014
19
An uncommon presentation of follicular thyroid carcinoma: when chronic back pain should raise a flag. ( 25508535 )
2014
20
Actual incidence and clinical behaviour of follicular thyroid carcinoma: an institutional experience. ( 24741369 )
2014
21
Follicular thyroid carcinoma with distant metastasis: outcome and prognostic factor. ( 24420337 )
2014
22
Spinal cord compression as initial presentation of metastatic occult follicular thyroid carcinoma. ( 24966555 )
2014
23
Iodophilic synchronous phalangeal and choroidal metastasis from follicular thyroid carcinoma: a case report and review. ( 25114878 )
2014
24
An uncommon presentation of follicular thyroid carcinoma: when chronic back pain should raise a flag. ( 25470908 )
2014
25
NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma. ( 24820091 )
2014
26
Prognostic factors of follicular thyroid carcinoma. ( 25156926 )
2014
27
A rare case of solitary subcutaneous scalp metastasis from follicular thyroid carcinoma revealed with positron emission tomography/computed tomography: a case report and review. ( 25022416 )
2014
28
Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas. ( 24631480 )
2014
29
Follicular thyroid carcinoma presenting as a soft tissue thigh mass. ( 24703053 )
2014
30
Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma. ( 24684401 )
2014
31
Follicular thyroid carcinoma metastasis to the internal jugular vein demonstrated by 131I SPECT/CT. ( 24566419 )
2014
32
False-positive uptake of 124I in a laryngeal cyst mimicking thyroid remnant after thyroidectomy and 131i therapy for follicular thyroid carcinoma. ( 24561682 )
2014
33
FDG PET/CT in the detection of pancreatic metastasis in a patient with follicular thyroid carcinoma and negative I-131 whole body scan findings. ( 25224195 )
2014
34
Multidisciplinary approach to follicular thyroid carcinoma with giant mandibular and multiple sites metastases Case report. ( 25712423 )
2014
35
Clear cell variant of follicular thyroid carcinoma with normal thyroid-stimulating hormone value: a case report. ( 24884725 )
2014
36
Metastatic Follicular Thyroid Carcinoma Secreting Thyroid Hormone and Radioiodine Avid without Stimulation: A Case Report and Literature Review. ( 25400957 )
2014
37
Clinicopathological and prognostic analysis of follicular thyroid carcinoma in a single institute over a 15-year period. ( 24613740 )
2014
38
Macrofollicular variant of follicular thyroid carcinoma: a case report. ( 23564026 )
2013
39
Prognostic significance of patient age in minimally and widely invasive follicular thyroid carcinoma: Investigation of three age groups. ( 24390055 )
2013
40
Floating left innominate vein neoplastic thrombus: A rare case of mediastinal extension of follicular thyroid carcinoma. ( 24335091 )
2013
41
Molecular photoacoustic imaging of follicular thyroid carcinoma. ( 23349314 )
2013
42
An Unusual Association between Sweet's Syndrome and Metastatic Papillary Follicular Thyroid Carcinoma. ( 23467309 )
2013
43
The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma. ( 23563786 )
2013
44
Mandibular metastasis from follicular thyroid carcinoma: a rare case after twelve years. ( 23981162 )
2013
45
Are prognostic scoring systems of value in patients with follicular thyroid carcinoma? ( 24050927 )
2013
46
Loss of estrogen receptor Beta expression in follicular thyroid carcinoma predicts poor outcome. ( 23106428 )
2013
47
Follicular thyroid carcinoma with signet ring cell morphology: fine-needle aspiration cytology, histopathology, and immunohistochemistry. ( 24068558 )
2013
48
Benign Cystic Mesothelioma: False-Positive Iodine Accumulation in a Patient With Oncocytic Follicular Thyroid Carcinoma. ( 24217550 )
2013
49
Co-occurrence of Papillary and Follicular Thyroid Carcinoma in a Patient with Hodgkin's Disease. ( 24385788 )
2013
50
Disease-free survival in papillary and follicular thyroid carcinoma. Comparison between UICC 5th and 7th classifications of T stage, and the prognostic value of primary tumour size. ( 23483137 )
2013

Variations for Thyroid Cancer, Nonmedullary, 2

UniProtKB/Swiss-Prot genetic disease variations for Thyroid Cancer, Nonmedullary, 2:

71
# Symbol AA change Variation ID SNP ID
1 HRAS p.Gln61Lys VAR_045979 rs28933406
2 MINPP1 p.Ser41Leu VAR_022836 rs119486096
3 MINPP1 p.Gln270Arg VAR_022837 rs104894171
4 NRAS p.Gln61Arg VAR_006847 rs11554290
5 SRGAP1 p.Gln149His VAR_075879 rs781626187
6 SRGAP1 p.Ala275Thr VAR_075880 rs797044990
7 SRGAP1 p.Arg617Cys VAR_075882 rs114817817
8 SRGAP1 p.His875Arg VAR_075883 rs61754221

ClinVar genetic disease variations for Thyroid Cancer, Nonmedullary, 2:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 HRAS NM_005343.3(HRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs28933406 GRCh37 Chromosome 11, 533875: 533875
2 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
3 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
4 MINPP1 NM_004897.4(MINPP1): c.122C> T (p.Ser41Leu) single nucleotide variant Pathogenic rs119486096 GRCh37 Chromosome 10, 89264794: 89264794
5 MINPP1 NM_004897.4(MINPP1): c.809A> G (p.Gln270Arg) single nucleotide variant Pathogenic rs104894171 GRCh37 Chromosome 10, 89268264: 89268264
6 SRGAP1 NM_020762.3(SRGAP1): c.447A> C (p.Gln149His) single nucleotide variant Pathogenic rs781626187 GRCh38 Chromosome 12, 64016970: 64016970
7 SRGAP1 NM_020762.3(SRGAP1): c.823G> A (p.Ala275Thr) single nucleotide variant Pathogenic rs797044990 GRCh37 Chromosome 12, 64456718: 64456718
8 SRGAP1 NM_020762.3(SRGAP1): c.1849C> T (p.Arg617Cys) single nucleotide variant risk factor rs114817817 GRCh37 Chromosome 12, 64502747: 64502747

Cosmic variations for Thyroid Cancer, Nonmedullary, 2:

9 (show top 50) (show all 170)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM26450 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1456A>T p.I486F 31
2 COSM26419 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1897G>T p.D633Y 31
3 COSM26455 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1891T>A p.F631I 31
4 COSM26485 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1894A>G p.T632A 31
5 COSM26418 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1895C>T p.T632I 31
6 COSM43624 TP53 thyroid,NS,carcinoma,follicular carcinoma c.875A>G p.K292R 31
7 COSM10656 TP53 thyroid,NS,carcinoma,follicular carcinoma c.742C>T p.R248W 31
8 COSM5880107 SMAD4 thyroid,NS,carcinoma,follicular carcinoma c.1060G>C p.V354L 31
9 COSM5546625 SMAD4 thyroid,NS,carcinoma,follicular carcinoma c.767A>T p.Q256L 31
10 COSM1570338 RET thyroid,NS,carcinoma,follicular carcinoma c.2651A>T p.E884V 31
11 COSM5546623 RB1 thyroid,NS,carcinoma,follicular carcinoma c.2039T>C p.I680T 31
12 COSM5033 PTEN thyroid,NS,carcinoma,follicular carcinoma c.389G>A p.R130Q 31
13 COSM5034 PTEN thyroid,NS,carcinoma,follicular carcinoma c.425G>A p.R142Q 31
14 COSM23653 PTEN thyroid,NS,carcinoma,follicular carcinoma c.476G>A p.R159K 31
15 COSM23654 PTEN thyroid,NS,carcinoma,follicular carcinoma c.701G>A p.R234Q 31
16 COSM23652 PTEN thyroid,NS,carcinoma,follicular carcinoma c.496G>A p.V166I 31
17 COSM23651 PTEN thyroid,NS,carcinoma,follicular carcinoma c.353A>G p.H118R 31
18 COSM5224 PTEN thyroid,NS,carcinoma,follicular carcinoma c.370T>A p.C124S 31
19 COSM775 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3140A>G p.H1047R 31
20 COSM12458 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.1634A>C p.E545A 31
21 COSM29097 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.1649T>C p.F550S 31
22 COSM28547 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3180C>T p.H1060H 31
23 COSM17446 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3149G>A p.G1050D 31
24 COSM29096 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.1558G>A p.D520N 31
25 COSM28544 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3026G>A p.G1009E 31
26 COSM33601 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3155C>T p.T1052I 31
27 COSM33599 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3052G>A p.D1018N 31
28 COSM33598 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3002T>A p.L1001H 31
29 COSM33600 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3046T>C p.F1016L 31
30 COSM29095 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3001C>A p.L1001I 31
31 COSM584 NRAS thyroid,NS,carcinoma,follicular carcinoma c.182A>G p.Q61R 31
32 COSM564 NRAS thyroid,NS,carcinoma,follicular carcinoma c.35G>A p.G12D 31
33 COSM516 KRAS thyroid,NS,carcinoma,follicular carcinoma c.34G>T p.G12C 31
34 COSM520 KRAS thyroid,NS,carcinoma,follicular carcinoma c.35G>T p.G12V 31
35 COSM522 KRAS thyroid,NS,carcinoma,follicular carcinoma c.35G>C p.G12A 31
36 COSM518 KRAS thyroid,NS,carcinoma,follicular carcinoma c.34G>C p.G12R 31
37 COSM551 KRAS thyroid,NS,carcinoma,follicular carcinoma c.182A>C p.Q61P 31
38 COSM96533 IDH1 thyroid,NS,carcinoma,follicular carcinoma c.399T>A p.H133Q 31
39 COSM96532 IDH1 thyroid,NS,carcinoma,follicular carcinoma c.390A>G p.I130M 31
40 COSM500 HRAS thyroid,NS,carcinoma,follicular carcinoma c.182A>C p.Q61P 31
41 COSM498 HRAS thyroid,NS,carcinoma,follicular carcinoma c.182A>T p.Q61L 31
42 COSM28618 GNAS thyroid,NS,carcinoma,follicular carcinoma c.679C>A p.Q227K 31
43 COSM27900 GNAS thyroid,NS,carcinoma,follicular carcinoma c.681G>T p.Q227H 31
44 COSM27895 GNAS thyroid,NS,carcinoma,follicular carcinoma c.602G>A p.R201H 31
45 COSM13224 CDKN2A thyroid,NS,carcinoma,follicular carcinoma c.242C>T p.P81L 31
46 COSM5880106 APC thyroid,NS,carcinoma,follicular carcinoma c.4298C>T p.P1433L 31
47 COSM1570337 ALK thyroid,NS,carcinoma,follicular carcinoma c.3551G>A p.G1184E 31
48 COSM17721 VHL thyroid,NS,carcinoma,papillary carcinoma c.241C>T p.P81S 28
49 COSM26416 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1867G>T p.A623S 28
50 COSM26449 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1358T>C p.M453T 28

Expression for Thyroid Cancer, Nonmedullary, 2

Search GEO for disease gene expression data for Thyroid Cancer, Nonmedullary, 2.

Pathways for Thyroid Cancer, Nonmedullary, 2

Pathways related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.64 BRAF HRAS KDR NRAS RASSF1
2
Show member pathways
12.38 BRAF HRAS KDR NRAS PTEN
3
Show member pathways
12.29 BRAF HRAS NRAS PTEN
4 12.28 BRAF HRAS NRAS PAX8 PPARG PTEN
5 12.21 BRAF HRAS KDR NRAS
6
Show member pathways
12.17 BRAF HRAS NRAS PPARG
7
Show member pathways
12.16 BRAF HRAS KDR NRAS PAX8 PPARG
8
Show member pathways
12.13 HRAS KDR NRAS PTEN
9
Show member pathways
12.12 BRAF HRAS KDR NRAS PTEN
10
Show member pathways
12.08 BRAF HRAS NRAS PPARG
11
Show member pathways
11.99 BRAF HRAS NRAS PTEN
12 11.86 DIO2 HRAS NRAS THRB
13 11.8 BRAF HRAS NRAS PTEN
14 11.6 BRAF HRAS NRAS RASSF1
15
Show member pathways
11.58 BRAF HRAS NRAS
16 11.54 BRAF HRAS NRAS
17 11.54 BRAF HRAS PAX8 TSHR
18 11.48 HRAS NRAS PTEN RET
19
Show member pathways
11.47 BRAF HRAS KDR NRAS RET
20 11.42 HRAS NRAS RET
21 11.25 BRAF HRAS KDR NRAS
22 11.22 BRAF HRAS NRAS
23 11.13 HRAS NRAS PTEN
24 10.74 HRAS NRAS
25 10.21 TG TPO TSHR

GO Terms for Thyroid Cancer, Nonmedullary, 2

Biological processes related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.96 BRAF HRAS NRAS PPARG RASSF1 RET
2 MAPK cascade GO:0000165 9.85 BRAF HRAS NRAS RET
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.8 BRAF HRAS KDR PTEN
4 positive regulation of gene expression GO:0010628 9.8 BRAF HRAS NKX2-1 PTEN RET
5 axon guidance GO:0007411 9.78 HRAS NKX2-1 NRAS RET
6 Ras protein signal transduction GO:0007265 9.69 HRAS NRAS RASSF1
7 animal organ morphogenesis GO:0009887 9.62 BRAF HRAS NKX2-1 THRB
8 thyroid hormone generation GO:0006590 9.54 DIO2 TPO
9 cellular response to nerve growth factor stimulus GO:1990090 9.54 BRAF CALCA PTEN
10 positive regulation of adenylate cyclase activity GO:0045762 9.52 CALCA TSHR
11 thyroid hormone metabolic process GO:0042403 9.46 DIO2 TG
12 regulation of axon regeneration GO:0048679 9.43 BRAF PTEN
13 thyroid-stimulating hormone signaling pathway GO:0038194 9.16 PAX8 TSHR
14 hormone biosynthetic process GO:0042446 9.13 DIO2 TG TPO
15 thyroid gland development GO:0030878 8.92 BRAF NKX2-1 PAX8 TG

Molecular functions related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.55 NKX2-1 NME1 PPARG PTEN THRB
2 inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity GO:0051717 8.96 MINPP1 PTEN
3 thyroid-stimulating hormone receptor activity GO:0004996 8.62 PAX8 TSHR

Sources for Thyroid Cancer, Nonmedullary, 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....